Research and Markets: A Comprehensive Review of the UCB Company's Products and Performance.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c64617) has announced the addition of the Espicom report "UCB: Performance, Products, Pipeline and Potential" to their offering.

Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

"UCB is a global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of CNS disorders, allergy/respiratory diseases, immune and inflammatory disorders, plus oncology. Headquartered in Brussels, Belgium, it has over 8,500 employees worldwide. The Group has production and packaging facilities in Belgium, Switzerland, the US, Japan, Germany, India, Italy, Spain and South Korea (to be closed) and sells in more than 40 countries on all continents. During 2005, the Group disposed of the Surface Specialties business segment and transformed itself into a pure biopharmaceutical company.

In 2007, UCB's and Schwarz Pharma's financial accounts will be fully consolidated, which coupled with strong growth from Keppra, Xyzal and Zyrtec (in the US at least), should lead to positive results for UCB. Net sales growth will be offset by a decrease in royalty income due to the remaining effect of the Boss patent expiry in 2006. UCB expects to increase both R&D and capital expenditure, reflecting costs related to Cimzia's development and the restructuring charges associated with the take over of Schwarz.

UCB has streamlined its business model to create a fully-integrated global organisation. The commercial organisations have also been restructured into three separate units: Central Nervous System, Inflammation; and Primary Care, to give the company greater focus and resilience. UCB has the potential to bring a steady stream of large- and small-molecule products to market over the next five years and beyond. Where molecules have potential in primary care, as opposed to the core field of severe diseases, UCB intends to team up with major pharmaceutical companies with appropriate sales forces.

The company is investing in key technologies including antibody selection, biological scaffolds, SV2A biology, proprietary chemistry, and technology for integrating biology and chemistry. In total, UCB has a property estate of over 500 patent families and co-operates with 16 partner companies.

This new strategic analysis report UCB: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price.

For more information visit http://www.researchandmarkets.com/reports/c64617.